


Healthcare Resource Utilization (HCRU) and Direct Medical Costs Following Acute SARS-CoV-2 Infection: Findings From a Literature Review

Elzbieta Łukomska,¹ Krzysztof Kloc,¹ Malwina Kowalska,¹ Aleksandra Matjaszek,¹ Keya Joshi,² Stefan Scholz,³ Nicolas Van de Velde,² Ekkehard Beck^{2,*}

¹Assignity, Krakow, Poland; ²Moderna, Inc., Cambridge, MA, USA; ³Moderna, Munich, Germany

*Presenting author.



SUPPLEMENTAL METHODS

Literature Search Assumptions

- The study population included children and adults diagnosed with Long-COVID or post-acute COVID sequelae/conditions
- Due to Long-COVID often left undiagnosed, studies with long-term follow-up of patients after their COVID-19 diagnosis were also included (regardless of whether Long-COVID was diagnosed)
- Outcomes included long-term healthcare costs and/or healthcare resource utilization (HCRU) associated with a previous COVID-19 diagnosis, Long-COVID diagnosis, or post-acute COVID sequelae or conditions, expressed as a number, percentage, or other, if relevant
- Study types included observational, comparative, or single-arm studies, both retrospective and prospective, published as peer-reviewed journal articles, preprint journal articles, or country-specific reports
- No country restrictions were applied to PubMed or manual searches. Health Technology Assessment agencies website searches were restricted to European countries (EU4 and the United Kingdom), the United States, Canada, Australia, Korea, Taiwan, Israel, and Japan. Language was restricted to English

Studies Included in the Literature Review

1. Abdullah MS, et al. *Western Pac Surveill Response J*. 2023;14(1):1-9.
2. Ashman Kröönström L, et al. *PLoS One*. 2023;18(9):e0291548.
3. Ayoubkhani D, et al. *BMJ*. 2021;372:n693.
4. Castriotta L, et al. (2023). *SSRN*. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4496142
5. Chambers LC, et al. *Am J Manag Care*. 2023;29(11):566-572.
6. Comelli A, et al. *Front Med (Lausanne)*. 2022;9:834354.
7. Debski M, et al. *PLOS Glob Public Health*. 2022;2(11):e0001188.
8. DeMartino JK, et al. *J Manag Care Spec Pharm*. 2022;28(9):936-947.
9. Encinosa W, et al. *JAMA Netw Open*. 2023;6(1):e2244975.
10. Formoso G, et al. *BMJ Open*. 2023;13(3):e063493.
11. Fung KW, et al. *PLoS Med*. 2023;20(4):e1004194.
12. Gil S, et al. *J Am Med Dir Assoc*. 2023;24(1):10-16.
13. Gordon AS, et al. *Pediatr Res*. 2024;95(1):342-249.
14. Griffin D, et al. *BMJ Open*. 2023;13(8):e069247.
15. Hedberg P, et al. *J Intern Med*. 2023;293(2):246-258.
16. Heightman M, et al. *BMJ Open Respir Res*. 2021;8(1):e001041.
17. Hernandez-Romieu AC, et al. *MMWR Morb Mortal Wkly Rep*. 2021;70(17):644-650.
18. Khan T, et al. *J Am Board Fam Med*. 2024;36(6):883-891.
19. Kirchberger I, et al. *Viruses*. 2023;15(6):1326.
20. Koumpias AM, et al. *BMC Health Serv Res*. 2022;22(1):1010.
21. Lo T, et al. *CMAJ Open*. 2023;11(4):E706-E715.
22. Magnusson K, et al. *BMJ*. 2022;376:e066809.
23. McNaughton CD, et al. *CMAJ*. 2022;194(40):E1368-E1376.
24. Melnick G, O'Leary J. *Health*. 2023;15:177-185.
25. Menges D, et al. *PLoS One*. 2021;16(7):e0254523.
26. Miller MJ, et al. *Disabil Health J*. 2023;16(2):101436.
27. Mu Y, et al. *SSRN*. <http://dx.doi.org/10.2139/ssrn.4598962>
28. Murch BJ, et al. *Health Inf Manag*. 2023;52(3):167-175.
29. Nehme M, et al. *Sci Rep*. 2022;12(1):14505.
30. Nica S, et al. *Rom J Mil Med*. 2022;125(2):275-280.
31. Patterson B, et al. *Value Health*. 2022;25(7):S375-S375.
32. Pike J, et al. *Prev Chronic Dis*. 2023;20:E06.
33. Tartof SY, et al. *JAMA Netw Open*. 2022;5(8):e2225657.
34. Tene L, et al. *Int J Infect Dis*. 2023;128:3-10.
35. Tisler A, et al. *PLoS One*. 2022;17(11):e0278057.
36. Tufts J, et al. *BMC Prim Care*. 2023;24(1):245.
37. Walter N, et al. *Viruses*. 2022;14(12):2600.
38. Whittaker HR, et al. *medRxiv*. 2021.04.09.21255199.
39. Woldegiorgis M, et al. *medRxiv*. 2023.08.06.23293706.
40. Wolff Sagy Y, et al. *BMJ Glob Health*. 2023;8(7):e012588.
41. Zaidan M, et al. *Chest*. 2022;162(4):A519.

**Presented at the Annual Meeting for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR);
May 5-8, 2024; Atlanta, GA, USA**